Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18447109 | METHODS AND COMPOSITIONS RELATED TO ANTIBODY FRAGMENTS THAT BIND TO TUMOR-ASSOCIATED GLYCOPROTEIN 72 (TAG-72) | Non-Final OA | OHIO STATE INNOVATION FOUNDATION |
| 17808402 | ANTIBODIES AND METHOD OF PRODUCING ANTIBODIES | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18593853 | Immune Cell Fusion (ICF) and Uses Thereof | Non-Final OA | Trustees of Boston University |
| 17774685 | Anti-TIGIT Antibodies and Uses Thereof | Non-Final OA | Merck Patent GmbH |
| 17331296 | GENERATING VIRUS OR OTHER ANTIGEN-SPECIFIC T CELLS FROM A NAÏVE T CELL POPULATION | Non-Final OA | CHILDREN'S NATIONAL MEDICAL CENTER |
| 17767766 | ANTI-TN ANTIBODIES AND USES THEREOF | Non-Final OA | Emory University |
| 18158259 | USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING CANCERS | Non-Final OA | Neuracle Science Co., Ltd. |
| 18175345 | Methods of Treating High Risk Multiple Myeloma | Non-Final OA | Janssen Biotech, Inc. |
| 16797301 | Methods of Treating Newly Diagnosed Multiple Myeloma with a Combination of An Antibody that Specifically Binds CD38, Lenalidomide and Dexamethasone | Final Rejection | Janssen Biotech, Inc. |
| 17533065 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND INFECTIOUS DISEASES | Non-Final OA | Cedars-Sinai Medical Center |
| 17766280 | INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17144342 | ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 17811586 | BTLA-BINDING ANTIBODIES FOR MODULATING IMMUNE RESPONSE AND TREATING DISEASE | Non-Final OA | TRIANNI, Inc. |
| 18215953 | ANTI-CD33 AND ANTI-CD7 COMBINATION TREATMENT | Non-Final OA | BiVictriX Limited |
| 17253922 | NEOANTIGENS AND USES THEREOF | Non-Final OA | BioNTech US Inc. |
| 16761183 | TEST KITS AND ASSAYS | Non-Final OA | InsituGen Limited |
| 18098199 | USE OF RECOMBINANT LAG-3 OR THE DERIVATIVES THEREOF FOR ELICITING MONOCYTE IMMUNE RESPONSE | Final Rejection | IMMUTEP |
| 18145169 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | Final Rejection | SUBDOMAIN, LLC |
| 18002064 | CONDITIONALLY ACTIVE ANTI-NECTIN-4 ANTIBODIES | Non-Final OA | BIOATLA, INC. |
| 17542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | Non-Final OA | AVM Biotechnology, LLC |
| 17916642 | MEDICAMENT FOR KILLING TUMOR CELLS | Non-Final OA | PhotoQ3 Inc. |
| 17913775 | BI-SPECIFIC ANTIBODIES FOR USE IN PRODUCING ARMED IMMUNE CELLS | Non-Final OA | CYTOARM CO. LTD. |
| 17822710 | ANTI-CD137 CONSTRUCTS AND USES THEREOF | Non-Final OA | SHANGHAI HENLIUS BIOTECH, INC. |
| 17786423 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | Non-Final OA | FORMYCON AG |
| 17756836 | ANTIBODY FC REGION HAVING ENHANCED BINDING AFFINITY TO FCYRIIB | Non-Final OA | SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE |
| 17764850 | IgE Antibody with Fcgamma Receptor binding | Final Rejection | Epsilogen Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy